SINDROXOCIN 2mg / ml powder infusion solution medication leaflet

L01DB01 doxorubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances

Doxorubicinum is a chemotherapy drug used for the treatment of various types of cancer, including breast cancer, leukemia, and lymphoma. It belongs to the anthracycline class and works by inhibiting DNA synthesis in cancer cells, preventing their division and growth.

The medication is administered intravenously, usually as part of a specific regimen, under the supervision of an oncologist. It is effective in reducing tumor size and slowing disease progression.

Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and, in rare cases, cardiac toxicity. Close monitoring is essential during treatment.

Consult your doctor to discuss the benefits and risks of treatment with Doxorubicinum. This medication must be administered exclusively in controlled environments, such as hospitals.

General data about SINDROXOCIN 2mg / ml

Substance: doxorubicin

Date of last drug list: 01-03-2022

Commercial code: W52903001

Concentration: 2mg / ml

Pharmaceutical form: powder infusion solution

Packing volume: 8 ml

Product type: generic

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.

Marketing authorisation

Manufacturer: SINDAN-PHARMA S.R.L. - ROMANIA

Holder: TEVA PHARMACEUTICALS S.R.L. - ROMANIA

Number: 12943/2020/01

Shelf life: 4 years

Concentrations available for doxorubicin

10mg, 2mg/ml, 50mg

Other substances similar to doxorubicin